These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32596332)

  • 1. The Risk of Acute Kidney Injury in Hepatitis B Virus-Related Acute on Chronic Liver Failure with Tenofovir Treatment.
    Zhang K; Lin S; Wang M; Huang J; Zhu Y
    Biomed Res Int; 2020; 2020():5728359. PubMed ID: 32596332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir Versus Entecavir for the Treatment of Acute-on-Chronic Liver Failure due to Reactivation of Chronic Hepatitis B With Genotypes B and C.
    Wan YM; Li YH; Xu ZY; Wu HM; Xu Y; Wu XN; Yang JH
    J Clin Gastroenterol; 2019 Apr; 53(4):e171-e177. PubMed ID: 29659382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAg-positive cancer patients undergoing chemotherapy.
    Lee IC; Chao Y; Li CP; Su CW; Lan KH; Lin HC; Hou MC; Huang YH
    J Viral Hepat; 2018 Dec; 25(12):1599-1607. PubMed ID: 30125436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
    Li J; Hu C; Chen Y; Zhang R; Fu S; Zhou M; Gao Z; Fu M; Yan T; Yang Y; Li J; Liu J; Chen T; Zhao Y; He Y
    BMC Infect Dis; 2021 Jun; 21(1):567. PubMed ID: 34126939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of tenofovir alafenamide and entecavir for hepatitis B virus
    Peng W; Gu H; Jiang C; Liu J; Zhang J; Fu L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):194-201. PubMed ID: 35545409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
    Ha I; Chung JW; Jang ES; Jeong SH; Kim JW
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1774-1781. PubMed ID: 32154938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
    Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
    J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
    Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
    Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamivudine improves short-term outcome in hepatitis B virus-related acute-on-chronic liver failure patients with a high model for end-stage liver disease score.
    Li X; Gao F; Liu H; Zhang H; Liu Y; Ye X; Geng M; Sun L; Wang R; Li Y; Jiang Y; Wang X; Zhou G; Yang Z; Li A; Zeng H; Wang X
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):1-9. PubMed ID: 27749778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States.
    Kim WR; Telep LE; Jump B; Lu M; Ramroth H; Flaherty J; Gaggar A; Chokkalingam AP; Gordon SC
    Aliment Pharmacol Ther; 2022 Apr; 55(7):828-835. PubMed ID: 35137422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
    Wang YH; Liao J; Zhang DM; Wu DB; Tao YC; Wang ML; Chen EQ; Tang H
    J Med Virol; 2020 Mar; 92(3):302-308. PubMed ID: 31609007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study.
    Mak LY; Hoang J; Jun DW; Chen CH; Peng CY; Yeh ML; Kim SE; Huang DQ; Jeong JY; Yoon E; Oh H; Tsai PC; Huang CF; Ahn SB; Trinh H; Xie Q; Wong GLH; Enomoto M; Shim JJ; Lee DH; Liu L; Kozuka R; Cho YK; Jeong SW; Kim HS; Trinh L; Dao A; Huang R; Hui RW; Tsui V; Quek S; Khine HHTW; Ogawa E; Dai CY; Huang JF; Cheung R; Wu C; Chuang WL; Lim SG; Yu ML; Yuen MF; Nguyen MH
    Hepatol Int; 2022 Feb; 16(1):48-58. PubMed ID: 34822056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis.
    Han Y; Zeng A; Liao H; Liu Y; Chen Y; Ding H
    Int Immunopharmacol; 2017 Jan; 42():168-175. PubMed ID: 27915131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compare with safety and efficacy of entecavir and adefovir dipivoxil combination therapy and tenofovir disoproxil fumarate monotherapy for chronic hepatitis B patient with adefovir-resistant.
    Lai MC; Lian JS; Zhang WJ; Xu J; Zhou L; Zheng SS
    Math Biosci Eng; 2019 Oct; 17(1):627-635. PubMed ID: 31731368
    [No Abstract]   [Full Text] [Related]  

  • 15. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
    Lim YS; Byun KS; Yoo BC; Kwon SY; Kim YJ; An J; Lee HC; Lee YS
    Gut; 2016 May; 65(5):852-60. PubMed ID: 25596179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of tenofovir and entecavir in the development of acute kidney injury in cirrhotic chronic hepatitis B patients with refractory ascites.
    Tsai MC; Chang KC; Yen YH; Wu CK; Lin MT; Hu TH
    Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):208-213. PubMed ID: 32371826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice.
    Ha NB; Trinh HN; Rosenblatt L; Nghiem D; Nguyen MH
    J Clin Gastroenterol; 2016 Feb; 50(2):169-74. PubMed ID: 26018133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial.
    Iida-Ueno A; Enomoto M; Kozuka R; Tamori A; Kawada N
    J Med Virol; 2019 Jul; 91(7):1295-1300. PubMed ID: 30815880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir monotherapy after achieving complete viral suppression on entecavir plus tenofovir combination therapy.
    Kim LH; Chaung KT; Ha NB; Kin KC; Vu VD; Trinh HN; Nguyen HA; Nguyen MH
    Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):871-6. PubMed ID: 25919771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: Systematic review with meta-analysis.
    Lee HY; Oh H; Park CH; Yeo YH; Nguyen MH; Jun DW
    World J Gastroenterol; 2019 Jun; 25(23):2961-2972. PubMed ID: 31249453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.